Hikma Pharmaceuticals PLC (OTC: HKMPF) is a global drugmaker listed on the FTSE 100 index. The company develops, manufactures, and markets a range of pharmaceutical products. Its business is divided into key segments, including injectables and branded medicines, with a strong presence in the Middle East and North Africa.
On August 12, 2026, analyst firm Citigroup (NYSE: C) maintained its "Buy" rating for Hikma. At the time of this announcement, the stock price was $22.28. Citigroup also increased its price target for the company, raising it to 1,870.00 GBp from the previous 1,700.00 GBp, signaling confidence in the stock's future performance.
This positive outlook follows stronger-than-expected half-year results. As highlighted by Proactive Investors, Citi raised its group revenue forecasts for Hikma for 2026 to 2030 by approximately 1%. This upgrade is driven by higher expectations for the injectables business and for branded medicines in the Middle East and North Africa.
Other firms share this optimism. Deutsche Bank (NYSE: DB) also reiterated its 'buy' rating and increased its price target for Hikma to 2,050.00p from 1,950.00p. As highlighted by Proactive Investors, this decision was based on a strong first-half performance that was mainly driven by the company's branded division.
The strong analyst ratings are supported by solid financial figures. The company's core operating profit, which is profit from its main business activities, grew by 8.6% to $405.00 million. This figure was about 11% higher than what market experts had predicted. Adjusted earnings per share also beat expectations by 14%.
